Chemistry:MYCO-002
From HandWiki
MYCO-002 is an MDMA-like entactogen that is under development for the treatment of psychiatric disorders.[1][2][3] It is said to be being developed towards the aim of improving the safety profile of MDMA.[3] The drug is under development by Mydecine.[1][2] It was patented in July 2021 and received breakthrough therapy designation from the Food and Drug Administration (FDA) in November 2021.[1] As of November 2021, MYCO-002 is in the preclinical research for treatment of psychiatric disorders.[1][2] The chemical structure of MYCO-002 does not yet appear to have been disclosed.[1][2]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "MYCO 002". 28 November 2021. https://adisinsight.springer.com/drugs/800063539. "MYCO 002 is an entactogenic MDMA-like compound being developed by Mydecine Innovations for the potential treatment of mental disorders. [...]"
- ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on MYCO-002 with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/c93f49e0af48430f819d9f227c9c016b.
- ↑ 3.0 3.1 Mydecine Innovations Group (7 April 2021). "Mydecine Announces Four Lead Novel Drug Candidates and Prepares for Pre-IND Meetings with the FDA and Health Canada To Prepare For Human Clinical". https://www.globenewswire.com/news-release/2021/04/07/2205748/0/en/Mydecine-Announces-Four-Lead-Novel-Drug-Candidates-and-Prepares-for-Pre-IND-Meetings-with-the-FDA-and-Health-Canada-To-Prepare-For-Human-Clinical.html. "The four initial drug candidates include: [...] MYCO - 002 is an entactogenic compound that has been created with the goal of reducing harm and improving the safety profile vs. traditional MDMA."
 |  |
